Call Start: 08:00 January 1, 0000 9:01 AM ET

Precigen, Inc. (NASDAQ:PGEN)

Q1 2023 Earnings Conference Call

May 10, 2023 08:00 ET

Company Participants

Steve Harasym - Vice President, Investor Relations

Helen Sabzevari - President & Chief Executive Officer

Harry Thomasian - Chief Financial Officer

Conference Call Participants

Jason Butler - JMP Securities

Jennifer Kim - Cantor Fitzgerald

Carolina Ibanez Ventoso - Stifel

Arthur He - H.C. Wainwright

Operator

Good morning and welcome to the Precigen First Quarter 2023 Financial Results and Business Update Call. All participants will be in the listen-only mode. [Operator Instructions] Please note, this event is being recorded.

I would now like to turn the conference over to Steve Harasym, Vice President of Investor Relations. Please go ahead.

Steve Harasym

Thank you, Ryan and thank you to everyone joining us this morning. With me today are Dr. Helen Sabzevari, President and CEO of Precigen; as well as Harry Thomasian our CFO. Helen will provide an update on the progress we have made across our pipeline programs and highlight our upcoming milestones, after which Harry will review our first quarter 2023 financial results. Following our prepared remarks, we will open the call to Q&A.

Before we begin, I'd like to briefly review our forward-looking statements. During today's call, we will make various forward-looking statements. Investors are cautioned that our forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results or outcomes to differ from those indicated by our forward-looking statements. Please read the safe harbor statement as well as risk factors contained in present in the most recent SEC filings for a more complete discussion of the risks and uncertainties.

I would now like to turn the call over to Dr. Sabzevari. Helen?

Helen Sabzevari

Thanks, Steve and thanks to all of you for joining us today. Before I provide an update on our lead clinical programs, I want to emphasize the 4 clinical principles that are the foundation of our approach to innovating therapies that have the potential to transform patient care and outcomes. First, we focus on indications that have high unmet need and for which new therapeutic approaches are urgently needed.

Second, we strive to develop therapies that are differentiated, not only by the clinical benefit they provide but also by the potentially disruptive prices. a key limitation of many recent breakthrough therapies, especially those in the cell and gene therapy spaces is pricing that can create significant barriers to access and impose substantial financial burdens on health systems and payers. Thus, we are committed to innovating not only new treatment modalities but also novel modes of manufacture and delivery designed to enable more cost-effective pricing.